The 2014 Nature Letter by Pappas, Lanzavecchia and colleagues reconstructed the developmental pathways of human VH1-69-encoded broadly neutralizing antibodies to the conserved influenza A hemagglutinin (HA) stem and concluded that three features suffice for their rapid generation: a germline IGHV1-69 allele encoding phenylalanine 54, a permissive heavy-chain third complementarity-determining region (HCDR3), and a single somatic mutation (most often P52aA in HCDR2) that alone confers high-affinity binding, with later mutations rendering the founder mutations and even F54 functionally redundant. Four open issues arise from these findings: (1) the structural and thermodynamic mechanism by which non-contact founder mutations act and how redundancy emerges; (2) the quantitative frequency, across human populations, of naive B cell receptors meeting the three criteria (the third criterion being reachability of high-affinity binding by a single HCDR1/HCDR2 founder mutation), which determines population-level predictability of elicitation; (3) high-resolution mutational paths and fitness landscapes that produce breadth versus loss of breadth across influenza subtypes; and (4) immunogen designs and regimens that reproducibly select germline VH1-69 B cells, drive the founder mutation, and guide diversification toward breadth. All four issues remain open.

Background

Influenza A virus hemagglutinin (HA) — the major surface glycoprotein targeted by neutralizing antibodies — consists of a highly variable globular head that undergoes continuous antigenic drift and a far more conserved stem (stalk) region. A rare class of human antibodies that binds a conserved site on the HA stem can neutralize many influenza A subtypes and is a template for universal influenza vaccines. Most of these broadly neutralizing antibodies (bnAbs) use the heavy-chain variable gene IGHV1-69 (also written VH1-69), one of the inherited gene segments that encode the antibody heavy chain. The three heavy-chain complementarity-determining regions (HCDR1–HCDR3) are hypervariable loops that, together with the light-chain loops, form the antigen-binding site of the antibody (the paratope). The germline-encoded HCDR2 residue phenylalanine 54 (F54, numbered by the standard Kabat antibody numbering scheme) inserts into a conserved aromatic pocket around tryptophan 21 of the HA2 subunit (the stem portion of HA) on the stem. Notably, human IGHV1-69 exists as germline alleles that differ at position 54 — some encode F54, others leucine 54 — so this bnAb-permissive feature is polymorphic in the population. Antibody affinity and breadth improve during infection or vaccination by somatic hypermutation and selection in germinal centers (affinity maturation), and the isolated VH1-69 stem bnAbs known before 2014 were typically highly mutated, suggesting that many mutations might be needed to build them. Pappas et al. (Nature 516:418-422, 2014) characterized 197 anti-stem antibodies from a single donor, reconstructed the genealogies of several VH1-69 clones, and reached a strikingly simpler picture: germline-encoded F54 plus a permissive HCDR3 (most often a short HCDR3 bearing an aromatic residue, tyrosine 98, that occupies the same HA pocket) already poise the unmutated receptor, and in most analyzed lineages a single somatic mutation in HCDR1 or HCDR2 — classically proline-to-alanine at position 52a (P52aA), which does not itself contact HA — was sufficient to confer high-affinity binding to the selecting H1 HA, acting mainly by slowing the dissociation rate. As maturation continued, further mutations increased breadth of reactivity across subtypes and made the founder mutations, and eventually even germline F54, functionally redundant: reverting the founder mutation in a highly mutated descendant did not reduce binding. Genotyping 345 donors showed F54 allele frequencies of about 33% F/F, 56% F/L and 11% L/L, with lower anti-stem serum titers in young L/L donors, and the paper framed 'F54 allele, permissive VDJ rearrangement, single somatic mutation' as three requirements whose redundancy explains rapid elicitation in some but not all individuals. Four scientifically linked questions arising from these findings remain open. First, no structure, simulation, or thermodynamic account explains how a single non-contact mutation such as P52aA produces a large affinity gain, or how later mutations make the founder changes dispensable. Second, the population-level frequency of naive B cell receptors (BCRs) that simultaneously satisfy the three requirements — given IGHV1-69 allele polymorphism, VDJ recombination probabilities, and HCDR3 diversity — was not quantified, so the elicitation efficiency of this pathway across individuals and populations cannot yet be predicted. Third, the mutational paths and fitness landscapes that lead to breadth versus loss of breadth across diverse influenza subtypes were not mapped at high resolution, leaving the generality of the redundancy mechanism across allelic contexts and individuals uncharacterized; related work shows that alternative HCDR3 solutions exist, for example public motifs encoded by the IGHD3-9 gene segment and VH1-69 antibodies that approach the stem in different orientations. Fourth, the vaccine-design implication — which immunogens and regimens would reproducibly select the permissive germline VH1-69 B cells, drive the single required mutation, and then guide diversification toward breadth — remains to be empirically demonstrated. Subsequent work has built relevant tooling: molecular dynamics and free-energy calculations are now routinely applied to VH1-69 antibody-HA complexes, deep mutational scanning (high-throughput measurement of the binding effect of large libraries of antibody mutations) can map sequence constraints and epistasis (interactions between mutations), IGHV1-69-humanized mice and macaques with the homologous VH1-138 gene provide elicitation models, stem-only HA nanoparticles have entered phase 1 human trials, and large-cohort naive-repertoire sequencing plus IGHV genotyping make the population question empirically tractable.

Problem Statement

In the framework established by Pappas et al. (2014), generation of broadly neutralizing VH1-69 antibodies to the influenza A HA stem requires only (i) an IGHV1-69 allele encoding phenylalanine 54, (ii) a permissive HCDR3 (typically short, with an aromatic residue at position 98 occupying the conserved HA stem pocket), and (iii) a single somatic founder mutation in HCDR1/HCDR2 (classically P52aA) that suffices for high-affinity binding to the selecting H1 HA, with subsequent mutations increasing breadth and rendering the founder mutations and F54 functionally redundant. The open problem, whose facets jointly serve one objective — a mechanistic and quantitative account of this minimal pathway sufficient to predict and design its elicitation — is: (1) determine the structural and thermodynamic mechanism by which single non-contact founder mutations (P52aA, T28P and S30I are representative instances of the general class, not an exhaustive set, which must be characterized as a class) confer high-affinity stem binding, and how later compensatory mutations make the founder mutations and germline F54 dispensable; (2) quantify, across human populations, the frequency of naive B cell receptors whose germline configuration (a) uses an IGHV1-69 allele encoding F54, (b) carries a permissive HCDR3, whose membership is functional rather than fixed by sequence alone: an HCDR3 is permissive when, together with the F54-encoding IGHV1-69 allele of (a), it attains the high-affinity binding defined in (c) upon the single founder mutation of (c); the canonical permissive HCDR3s are short and bear an aromatic residue at position 98 occupying the conserved HA stem pocket, but length and residue 98 are typical rather than necessary features (the source's permissive HCDR3s occur with or without Y98), and (c) would attain high-affinity binding to the selecting H1 HA — operationally defined as a dissociation constant K_D in the low-nanomolar range (of order 1–10 nM, the affinity class of the paper's single-mutation branchpoint antibodies, such as BP9-1 at K_D ≈ 3.3 nM) — upon a single HCDR1/HCDR2 founder mutation drawn from the general class of single non-contact founder mutations shown sufficient in the paper's major pathway (the unmutated-common-ancestor-plus-one-mutation configuration, with P52aA the canonical instance), accounting for IGHV1-69 F54 allele and copy-number polymorphism, VDJ recombination probabilities, and HCDR3 diversity, so that the efficiency with which individuals and populations can mount VH1-69 broadly neutralizing responses becomes predictable; (3) map at high resolution the mutational paths and binding-fitness landscapes across diverse influenza subtypes that lead to breadth versus loss of breadth, establishing how general the redundancy mechanism is across VH1-69 allelic contexts, lineages, and individuals; and (4) identify immunogen designs and immunization regimens that reproducibly select the permissive germline VH1-69 B cells, drive the single required somatic mutation, and then guide diversification toward breadth. The four facets are jointly posed and address one objective.

References

  1. Pappas L, Foglierini M, Piccoli L, Kallewaard NL, Turrini F, Silacci C, Fernandez-Rodriguez B, Agatic G, Giacchetto-Sasselli I, Pellicciotta G, Sallusto F, Zhu Q, Vicenzi E, Corti D, Lanzavecchia A (2014). Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516(7531):418-422. doi:10.1038/nature13764, https://doi.org/10.1038/nature13764
  2. Avnir Y, Watson CT, Glanville J, Peterson EC, Tallarico AS, Bennett AS, Qin K, Fu Y, Huang CY, Beigel JH, Breden F, Zhu Q, Marasco WA (2016). IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Scientific Reports 6:20842. doi:10.1038/srep20842, https://doi.org/10.1038/srep20842
  3. Lees WD, Stejskal L, Moss DS, Shepherd AJ (2017). Investigating Substitutions in Antibody-Antigen Complexes Using Molecular Dynamics: A Case Study with Broad-spectrum, Influenza A Antibodies. Frontiers in Immunology 8:143. doi:10.3389/fimmu.2017.00143, https://doi.org/10.3389/fimmu.2017.00143
  4. Lang S, Xie J, Zhu X, Wu NC, Lerner RA, Wilson IA (2017). Antibody 27F3 Broadly Targets Influenza A Group 1 and Group 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem. Cell Reports 20(12):2935-2943. doi:10.1016/j.celrep.2017.08.084, https://doi.org/10.1016/j.celrep.2017.08.084
  5. Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA (2018). Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene. Cell Host & Microbe 24(4):569-578.e4. doi:10.1016/j.chom.2018.09.010, https://doi.org/10.1016/j.chom.2018.09.010
  6. Sangesland M, Ronsard L, Kazer SW, Bals J, Boyoglu-Barnum S, Yousif AS, Barnes R, Feldman J, Quirindongo-Crespo M, McTamney PM, Rohrer D, Lonberg N, Chackerian B, Graham BS, Kanekiyo M, Shalek AK, Lingwood D (2019). Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. Immunity 51(4):735-749.e8. doi:10.1016/j.immuni.2019.09.001, https://doi.org/10.1016/j.immuni.2019.09.001
  7. Vieira MC, Palm AK, Stamper CT, Tepora ME, Nguyen KD, Pham TD, Boyd SD, Wilson PC, Cobey S (2023). Germline-encoded specificities and the predictability of the B cell response. PLOS Pathogens 19(8):e1011603. doi:10.1371/journal.ppat.1011603, https://doi.org/10.1371/journal.ppat.1011603
  8. Teo QW, Wang Y, Lv H, Tan TJC, Lei R, Mao KJ, Wu NC (2023). Stringent and complex sequence constraints of an IGHV1-69 broadly neutralizing antibody to influenza HA stem. Cell Reports 42(11):113410. doi:10.1016/j.celrep.2023.113410, https://doi.org/10.1016/j.celrep.2023.113410
  9. Andrews SF, Cominsky LY, Shimberg GD, Gillespie RA, Gorman J, Raab JE, Brand J, Creanga A, Gajjala SR, Narpala S, Cheung CSF, Harris DR, Zhou T, Gordon I, Holman L, Mendoza F, Houser KV, Chen GL, Mascola JR, Graham BS, Kwong PD, Widge A, Dropulic LK, Ledgerwood JE, Kanekiyo M, McDermott AB (2023). An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Science Translational Medicine 15(692):eade4976. doi:10.1126/scitranslmed.ade4976, https://doi.org/10.1126/scitranslmed.ade4976
  10. Ray R, Nait Mohamed FA, Maurer DP, Huang J, Alpay BA, Ronsard L, Xie Z, Han J, Fernandez-Quintero M, Phan QA, Ursin RL, Vu M, Kirsch KH, Prum T, Rosado VC, Bracamonte-Moreno T, Okonkwo V, Bals J, McCarthy C, Nair U, Kanekiyo M, Ward AB, Schmidt AG, Batista FD, Lingwood D (2024). Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses. Immunity 57(5):1141-1159.e11. doi:10.1016/j.immuni.2024.03.022, https://doi.org/10.1016/j.immuni.2024.03.022
  11. Ataca S, Sangesland M, de Paiva Fróes Rocha R, Torrents de la Peña A, Ronsard L, Boyoglu-Barnum S, Gillespie RA, Tsybovsky Y, Stephens T, Moin SM, Lederhofer J, Creanga A, Andrews SF, Barnes RM, Rohrer D, Lonberg N, Graham BS, Ward AB, Lingwood D, Kanekiyo M (2024). Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem. Cell Reports 43(12):114990. doi:10.1016/j.celrep.2024.114990, https://doi.org/10.1016/j.celrep.2024.114990
  12. deCamp AC, Corcoran MM, Fulp WJ, Willis JR, Cottrell CA, Bader DLV, Kalyuzhniy O, Leggat DJ, Cohen KW, Hyrien O, Menis S, Finak G, Ballweber-Fleming L, Srikanth A, Plyler JR, Rahaman F, Lombardo A, Philiponis V, Whaley RE, Seese A, Brand J, Ruppel AM, Hoyland W, Mahoney CR, Cagigi A, Taylor A, Brown DM, Ambrozak DR, Sincomb T, Mullen TM, Maenza J, Kolokythas O, Khati N, Bethony J, Roederer M, Diemert D, Koup RA, Laufer DS, McElrath JM, McDermott AB, Karlsson Hedestam GB, Schief WR (2024). Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming. npj Vaccines 9:58. doi:10.1038/s41541-024-00811-5, https://doi.org/10.1038/s41541-024-00811-5
  13. Feldman J, Ramos ASF, Vu M, Maurer DP, Rosado VC, Lingwood D, Bajic G, Schmidt AG (2025). Human naïve B cells recognize prepandemic influenza virus hemagglutinins. Science Immunology 10(103):eado9572. doi:10.1126/sciimmunol.ado9572, https://doi.org/10.1126/sciimmunol.ado9572
  14. Sangesland M, Li N, Tsybovsky Y, Rodgers MD, Han J, Rodriguez AJ, Ferguson JA, Henry AR, Smith SC, Roberts-Torres J, Gillespie RA, Liu C, Merriam JS, Stephens T, Williams C, Walker E, Corcoran M, Ravichandran M, Creanga A, Andrews SF, Pierson TC, Karlsson Hedestam GB, Schramm CA, Reed DS, Douek DC, Zhou T, Ward AB, Kanekiyo M (2025). Functional, immunogenetic, and structural convergence in influenza immunity between humans and macaques. Science Translational Medicine 17(815):eady3570. doi:10.1126/scitranslmed.ady3570, https://doi.org/10.1126/scitranslmed.ady3570
  15. Dailey K, Wang Y, Teo QW, Wang C, Lei R, Tong M, Rodriguez LA, Wang L, Wu NC (2025). Vulnerability in the breadth evolution of an influenza broadly neutralizing antibody. bioRxiv 2025.11.03.686356. doi:10.1101/2025.11.03.686356, https://doi.org/10.1101/2025.11.03.686356